Inhibrx Biosciences (INBX) Net Margin (2023 - 2025)
Inhibrx Biosciences (INBX) posted quarterly Net Margin of 2204.15% for Q2 2025, down 186021515.0% year-over-year from N/an in Q2 2024, and up 95.4% quarter-over-quarter from 47865.0% in Q4 2024.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Net Margin (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Net Margin for 3 consecutive years, with 2204.15% the latest figure, recorded in Q2 2025.
- In Q2 2025, Net Margin fell 186021515.0% year-over-year to 2204.15%; the TTM figure through Dec 2025 stood at 10003.93% (down 10201985.0% YoY), while the FY2025 annual figure was 10773.46%, down 85455946.0% from the prior year.
- Net Margin improved to 2204.15% in Q2 2025 per INBX's latest filing, from 47865.0% in the prior quarter.
- Across five years, Net Margin topped out at 1858011.0% in Q2 2024 and bottomed at 156840.0% in Q2 2023.
- Historically, Net Margin has averaged 266992.19% across 3 years, with a median of 24574.34% in 2023.
- Annual changes were most pronounced in 2024 — Net Margin surged 201485100 bps — and 2025, when it slumped 186021515 bps.
- Inhibrx Biosciences' Net Margin stood at 5628.52% in 2023, then sank by 750 bps to 47865.0% in 2024, then soared by 95 bps to 2204.15% in 2025.
- Business Quant data shows INBX's Net Margin at 2204.15% in Q2 2025, 47865.0% in Q4 2024, and 1858011.0% in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 12.09% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -2,204.15% |
| Dec 31, 2024 | -47,865.00% |
| Jun 30, 2024 | 1,858,011.00% |
| Dec 31, 2023 | -5,628.52% |
| Sep 30, 2023 | -43,520.17% |
| Jun 30, 2023 | -156,840.00% |